Candesartan in Heart Failure—Preserved - CHARM-Preserved

Description:

The goal of the CHARM Preserved trial was to evaluate the effects of the long-acting angiotensin II type 1 receptor blocker candesartan compared with placebo in patients with symptomatic heart failure (HF) and an ejection fraction (EF) >40%.